Literature DB >> 15027488

The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice.

Emma Jones1, Denise Golgher, Anna Katharina Simon, Michaela Dahm-Vicker, Gavin Screaton, Tim Elliott, Awen Gallimore.   

Abstract

CD25+ regulatory T cells comprise 5-10% of CD4+ T cells in naïve mice and have been shown in several in vivo murine models to prevent the induction of autoimmune disease and inflammatory disease. Since T cells, which mediate autoimmunity, can through recognition of self-antigens also target tumour cells, it was postulated that CD25+ regulatory cells would also inhibit the generation of immune responses to rumours. Depletion of these cells using CD25-specific monoclonal antibodies has indeed been shown to promote rejection of several transplantable murine tumour cell lines including melanoma, leukaemia and colorectal carcinoma. Results obtained using these models indicate that in the absence of regulatory cells, CD4+ T cells mediate tumour immunity, although the precise mechanisms through which these cells result in tumour rejection have not yet been elucidated. The target antigens recognized by these CD4+ T cells have also not yet been identified. Immunization of mice with tumour cells in the absence of CD25+ regulatory cells does, however, induce immunity against a variety of different tumour cell lines indicating that the target antigen(s) are shared amongst tumours of distinct histological origins. Since CD25+ regulatory cells have been identified in humans, the possibility that the cells inhibit immune responses to shared rejection antigens expressed by human tumours is worthy of investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027488

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  5 in total

1.  Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy.

Authors:  Michal Kuczma; Agnieszka Kurczewska; Piotr Kraj
Journal:  J Immunotoxicol       Date:  2013-12-19       Impact factor: 3.000

2.  Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.

Authors:  Peter Attia; Ajay V Maker; Leah R Haworth; Linda Rogers-Freezer; Steven A Rosenberg
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

3.  Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Authors:  Peter Attia; Daniel J Powell; Ajay V Maker; Robert J Kreitman; Ira Pastan; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

Review 4.  Therapeutic use of Aldara in chronic myeloid leukemia.

Authors:  Annette M Marleau; Jeffrey H Lipton; Neil H Riordan; Thomas E Ichim
Journal:  J Transl Med       Date:  2007-01-25       Impact factor: 5.531

5.  Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.

Authors:  Stefanie J Mandl; Ryan B Rountree; Tracy B Dela Cruz; Susan P Foy; Joseph J Cote; Evan J Gordon; Erica Trent; Alain Delcayre; Alex Franzusoff
Journal:  J Immunother Cancer       Date:  2014-10-14       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.